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ABSTRACT 
Type 2 diabetes mellitus (T2D) is a major non-communicable disease and an important 
health burden worldwide, especially in the developing countries including Vietnam. 
Gynostemma pentaphyllum has been widely used in Vietnam as a herbal medicine for 
the prevention and treatment of T2D but the mechanism related to its effects is 
unknown. 
This thesis aims to evaluate the anti-diabetic effect and safety of GP extract (tea) in 
T2D patients and to investigate the major mechanisms of action of GP in T2D patients 
and in Goto-Kakizaki (GK) rats.  
The medication was provided as GP tea (dose 6g/day). The studies were implemented 
on newly diagnosed T2D patients to investigate the anti-diabetic effect of GP tea 
(Paper I), the effect of GP tea as add-on therapy with sulfonylurea (SU) (Paper II), 
and the effect of GP tea on insulin sensitivity (Paper III). Effects of GP tea on glucose 
tolerance and hepatic glucose output (HGO) were studied in GK rats (Paper IV). There 
was a randomized, placebo-controlled, double blind design for Papers I, II and IV, 
and a cross-over design for Paper III.  
Significant anti-diabetic effects and improved insulin sensitivity of GP tea were clearly 
demonstrated in Paper I. After 12 weeks of treatment, fasting plasma glucose (FPG) 
levels decreased 3.0 ± 1.8 mmol/l in the GP group, compared to a decrease of 0.6 ± 2.2 
mmol/l in the control group (p < 0.01). HbA1C levels decreased approximately 2%-units 
in the GP group, compared to 0.2%-unit in the controls (p < 0.001). Changes in 
Homeostasis Model Assessment-Insulin Resistance between baseline and the 12th 
week indicated that insulin resistance decreased significantly in the GP group (-2.1 ± 
3.0) compared with that (+1.1 ± 3.3) in the control group (p < 0.05). As add-on therapy 
to SU, GP tea further improved glycemic control and this improvement was sustained 
over 12 weeks (Paper II). After 4 weeks of SU treatment, FPG and HbA1C decreased 
significantly (p < 0.001). FPG was further reduced after add-on therapy by 2.9 ± 1.7 
and 0.9 ± 0.6 mmol/l in the GP and control groups, respectively (p < 0.001). HbA1C 
levels decreased approximately 2%-units in the add-on GP group compared to       
0.7%-units in the controls (p < 0.001). Furthermore, there were potential benefits of 
maintaining low-dose SU without symptoms of hypoglycemia. The biosecurity of GP 
tea was suggested clinically, since no hepatotoxicity, nephrotoxicity or other adverse 
effects were observed in the trials. The GP tea exerted anti-diabetic effects by 
improving insulin sensitivity, as demonstrated in the placebo-controlled cross-over 
study using the somatostatin-insulin-glucose infusion test (SIGIT) (Paper III). FPG 
and steady-state plasma glucose (SIGIT mean) were lower after GP treatment, 
compared to placebo treatment (p < 0.001). These glycometabolic improvements were 
achieved without any major change of circulating insulin levels. Finally, oral 
administration of GP tea for three weeks to GK rats exerted anti-diabetic effects by 
reducing plasma glucose (PG) levels and suppressing HGO levels significantly (Paper 
IV). The PG levels decreased from 9.8 ± 0.6 to 6.8 ± 0.4 mmol/L (p = 0.027) in GP-
treated rats, whereas PG levels were not significantly decreased in the placebo rats. 
Glucose tolerance, assessed by an intra-peritoneal glucose tolerance test, was 
significantly improved in GP-treated rats, compared to placebo-treated group (areas 
under the glucose curves, AUCs, from 0 to 120 min were 1150 ± 200 vs. 1761 ± 87 
mmol/L; p = 0.013). The glucose response in an intra-peritoneal pyruvate tolerance test 
was significantly lower in the GP group, indicating suppression of gluconeogenesis by 
GP treatment. In liver perfusions, the AUCs for HGO during 18 min (0-18 min) were 
significantly decreased in GP-treated rats, compared with control rats (302.8 ± 36.5 vs. 
423.5 ± 44.7 µmol, p < 0.05). Three-week GP treatment significantly reduced hepatic 
glycogen content, but not glycogen synthase activity (p < 0.007), compared to the 
placebo group.   
Our studies indicate that GP tea improves glucose tolerance and FPG, most likely by 
increasing insulin sensitivity and suppressing HGO. GP tea could offer an alternative to 
the addition of other oral medications in the treatment of T2D patients in Vietnam. 
Keywords: Herbal medicine; Type 2 diabetes; Gynostemma pentaphyllum tea; 
Insulin sensitivity; Sulfonylureas; Glucose tolerance. 
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1 INTRODUCTION 
 
Type 2 diabetes mellitus (T2D) is one of the major non-communicable diseases and 
recognized as an important health burden worldwide, because it is highly prevalent in 
the general population and causes substantial morbidity, mortality, and long-term 
complications [1,2]. It now represents one of the most challenging public health 
problems of the 21st century. The global prevalence of type 2 diabetes mellitus is 
projected to increase from 2.8% in 2000 to 4.4% in 2030, with the actual number of 
people with the disease doubling during the same period [3]. A large increase in this 
global prevalence will take place in the developing world, with approximately 80% of 
all new cases expected to appear in these countries by 2025 [4,5]. The Asia-Pacific 
region, including Vietnam, has been identified as of prime importance to the 
epidemiology of diabetes [6,7] because the prevalence of T2D in this part of the world 
is higher than in other developing countries [1]. In Vietnam, in the early of 1990s, the 
reported prevalence of diabetes in the two largest cities, Hanoi and Ho Chi Minh City, 
was 1.2% and 2.5% respectively [8,9]. In 2002, however, the prevalence increased to 
2.7% in Hanoi [10] and 4.8% and 6.9% in rural and urban areas, respectively, of Ho 
Chi Minh City [9]. This is possibly reflecting the result of lifestyle changes known as 
the “Nutrition Transition,” characterized by over-consumption of food, increased 
consumption of total fat, animal fat, and protein, as well as decreased physical activity 
[11]. 
Knowledge of the pathogenesis of T2D is important in understanding the appropriate 
modes of treatment. T2D is a heterogeneous syndrome due to the interaction of 
various environmental factors with multiple diabetogenic genes, which cause various 
combinations of beta cell failure and insulin resistance. Both defects are partly 
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genetically and environmentally determined, and both are exacerbated by 
hyperglycemia (“glucose toxicity”) [12,13]. Genetic predisposition accounts for 40-
80% of susceptibility to T2D and is polygenic. So far, most of T2D-associated genes 
relate to beta cell function and insulin secretion, or unknown functions [14,15] 
Environmental risk factors for T2D include obesity (which accounts for 90% of 
acquired risk) and physical inactivity, which decreases insulin sensitivity. About 55 
percent of T2D patients are obese at diagnosis [16]; chronic obesity leads to the 
increased insulin resistance that can develop into T2D, most likely because adipose 
tissue (especially that in the abdomen around internal organs) is a source of several 
types of molecules, including hormones and cytokines, which signal to other tissues. 
Inflammatory cytokines, for example, may activate the NF-κB pathway which has 
been linked to the development of insulin resistance [17]. Other research shows that 
T2D causes obesity due to changes in metabolism and a gradual failure of cells, 
leading to insulin resistance [18]. However, environmental factors (almost probably 
diet and weight) play a large part in the development of T2D, in addition to any 
genetic component. This can be seen from the adoption of the T2D epidemiological 
pattern in those who have moved to a different environment as compared to the same 
genetic pool who have not, e.g. in immigrants to Western developed countries, as 
compared to their relatives in lower incidence countries of origin [19]. Such 
developments can also be found in environments which have had a recent increase in 
social wealth, increasingly common throughout Asia. 
Insulin resistance is first demonstrated in skeletal muscle, in which higher 
concentrations of insulin are necessary to allow glucose to enter cells. Extra-hepatic 
insulin resistance predicts the development of T2D [13,20] and is detected in 
normoglycemic first-degree relatives of patients with T2D [21-23]. It is influenced by 
both genetic and environmental (for example, obesity) factors. Insulin-resistant 
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individuals frequently exhibit a constellation of other characteristics, including 
visceral obesity, dyslipidemia, hypertension, hyperinsulinemia, impaired fibrinolysis, 
endothelial dysfunction, hyperuricemia, vascular inflammation, and premature 
atherosclerosis [24]. Such individuals are said to have the metabolic syndrome [25], 
or insulin resistance syndrome, and emphasize the pathogenic role of insulin 
resistance. Initially, in the face of insulin resistance, compensatory increases in 
pancreatic insulin secretion may be able to maintain normal glucose concentrations. 
However, as the disease progresses, due to inherited beta cell impairments, insulin 
production gradually diminishes, leading to progressive stages of hyperglycemia. 
Hyperglycemia is first exhibited in the postprandial state, since uptake by skeletal 
muscle is the metabolic fate of the majority of ingested carbohydrate energy, and then 
during fasting. As insulin secretion decreases, hepatic glucose production, normally 
attenuated by insulin, increases. This increase is primarily responsible for the 
elevation of fasting glucose levels in patients with T2D. Superimposed upon these 
mechanisms is the well-recognized deleterious effect of hyperglycemia itself – 
glucotoxicity - upon both insulin sensitivity and insulin secretion [26]. Adipose tissue 
plays an important but often overlooked role in the pathogenesis of T2D. Insulin 
resistance is also demonstrated at the adipocyte level, leading to unrestrained lipolysis 
and elevation of circulating free fatty acids. Increased free fatty acids, in turn, further 
dampen the insulin response in skeletal muscle [27] while further impairing 
pancreatic insulin secretion as well as augmenting hepatic glucose production 
(“lipotoxicity”) [28]. Therefore, T2D results from coexisting defects at multiple organ 
sites: resistance to insulin action in muscle, defective pancreatic insulin secretion, and 
unrestrained hepatic glucose production, all of which are worsened by defective 
insulin action in fat. These pathophysiological lesions are to blame for the 
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development and progression of hyperglycemia. They are also the primary targets for 
pharmacological therapy. 
1.1 TREATMENT OF TYPE 2 DIABETES  
The goal in treating T2D is to maintain blood glucose concentrations within normal 
limits and to prevent the development of long-term complications of the disease. 
Weight reduction, exercise and dietary modification decrease insulin resistance and 
correct the hyperglycemia of T2D in some patients. Oral hypoglycemic agents and 
insulin therapy may be required to achieve satisfactory serum glucose levels. In 
addition, treatment of dyslipidemia, hemostatic disturbances and hypertension may be 
indicated. 
Non-pharmacological therapy 
Diet, exercise, and weight loss are at the center of any therapeutic diabetes program. 
Not only do these lifestyle modifications lower blood glucose concentrations, they also 
ameliorate many of the frequently coexisting risk factors for cardiovascular disease. 
Unfortunately, most patients are unable to achieve adequate control with lifestyle 
interventions alone, which should not detract from their critical role, since they enhance 
the effectiveness of medical regimens. An energy-controlled diet and regular aerobic 
exercise are therefore recommended for the majority of patients with T2D, who are 
usually overweight [29,30]. 
Pharmacological Therapy 
A number of oral anti-hyperglycemic agents have been introduced in recent years, 
each with its own mode of action. For example, reversal of the above mentioned 
defects, either individually or in concert, improves glycemic control: sulfonylureas, 
metformin, α-glucosidase inhibitors, thiazolidinediones, nonsulfonylurea insulin 
secretagogues, glucagon-like peptide 1 (GLP-1) analogues and dipeptidyl peptidase-4 
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(DPP4) inhibitors. An understanding of their mechanisms of action is important for 
their proper use, especially when they are administered in combination. Sulfonylureas 
(SU) bind to the sulfonylurea receptor, found on the surface of pancreatic beta cells. 
This interaction leads to a closure of ATP-dependent potassium (KATP) channels, 
facilitating cell membrane depolarization, calcium entry into the cell through voltage-
dependent calcium channels, and insulin secretion [31]. Thus, SU allow for insulin 
release at lower glucose thresholds than normal. They partially reverse the attenuated 
insulin secretion that characterizes T2D. Understandably, in the face of SU therapy, 
circulating insulin concentrations are increased. As a result, and despite the presence 
of insulin resistance, glucose concentrations fall. SU increase insulin secretion and 
they often lead to weight gain and may cause hypoglycemia [31].  
Metformin induces suppression of hepatic glucose output [32] and may also increase 
glucose uptake in muscle via stimulation of AMP kinase [33]. In patients with 
diabetes, metformin lowers plasma glucose concentrations both alone [34,35] and in 
combination with SU [35-37] while simultaneously decreasing plasma insulin 
concentrations. A third category of drugs, a-glucosidase inhibitors, decreases 
postprandial plasma glucose concentrations by delaying the absorption of 
carbohydrates [38]. Thiazolidinedione (TZD) acts by increasing overall insulin 
sensitivity with evidence of effects in both the liver, the primary glucose-producing 
organ, and skeletal muscle, the main site of glucose disposal [31]. TZD is effective 
both when given alone and when given in combination with either SU or metformin 
[31,39]. Meglitinides (repaglinidin and nataglinide) help the pancreas produce insulin 
and are often called "short-acting secretagogues". They act on the same potassium 
channels as SU, but at a different binding site [40]. By closing the potassium channels 
of the pancreatic beta cells, they open the calcium channels, hence enhancing insulin 
secretion [40]. The most recent additions to this armamentarium of anti-diabetic 
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drugs are the DPP4 inhibitors and GLP-1 analogues, which work by increasing blood 
concentrations of the incretin GLP-1, which in turn increases insulin production from 
pancreatic beta cells. They also lower glucagon release from pancreatic alpha cells, 
which causes reduced hepatic glucose production and may decrease body weight by 
reducing food intake.  Although a growing number of oral pharmacologic options are 
now available for management of T2D, acting through a variety of mechanisms that 
confer additive glucose lowering effects, the effectiveness of such therapies still 
remains inadequate [31]. In addition, all oral anti-diabetic agents have side effects. 
SU and the shorter-acting insulin secretagogues are associated with weight gain and 
hypoglycemia [31]. The major side effects of metformin and the GLP-1 analogues are 
seen in the gastrointestinal tract, with nausea, cramps, and diarrhea or constipation, 
respectively [31]. The major side effect of α-glucosidase inhibitors is flatulence, 
which occurs when undigested carbohydrate enters the large bowel, where it is 
digested by colonic bacteria resulting in gas formation [31]. At high doses or in the 
presence of renal decompensation, hepatic necrosis may occur due to high serum a-
glucosidase levels. The main side effect of TZD is water retention, leading to edema, 
generally a problem in less than 5% of individuals, but a big problem for some and in 
those with with significant water retention, potentially leading to decompensation of 
previously unrecognized heart failure. Therefore, TZD should be prescribed with both 
caution and patient warnings about the potential for water retention/weight gain, 
especially in patients with decreased ventricular function (NYHA grade III or IV 
heart failure). Recent studies have shown that there may be an increased risk of 
coronary heart disease and heart attacks with rosiglitazone [41] and a possible link 
between pioglitazone and bladder cancer [42] and osteoporotic fractures [43]. With 
increasing reliance on multiple patented pharmacological agents to meet glucose 
targets, the cost of treatment has also become a real concern. The cost of metformin 
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and sulfonylureas is much lower than that of the meglitinides, TZD, GLP-1 analogues 
and DPP4 inhibitors [44]. The ability of developing countries, such as Vietnam, to 
afford this level of treatment is dubious. These concerns point to the need for more 
effective, safer and less expensive management. Complementary and alternative 
medicine approaches that include herbs may hold promise in this regard; this research 
has focused on novel approaches to the treatment of T2D.  
1.2 TREATMENT OF T2D IN TRADITIONAL MEDICINE 
Many modern pharmaceuticals used in conventional medicine today also have natural 
plant origins. Among them, metformin was derived from the flowering plant, Galega 
officinalis (Goat’s Rue or French Lilac), which was a common traditional remedy for 
diabetes [45,46]. Plant derivatives with purported hypoglycemic properties have been 
used in folk medicine and traditional healing systems around the world (e.g., Native 
American Indian, Jewish, Chinese, East Indian, Mexican, Vietnamese [47]). Traditional 
herbal medicines have played a major role in the management of diabetes in Vietnam 
and many Asian countries for centuries [47]. Several hundred plants are known to have 
anti-diabetic properties, and a large number of compounds from plant extracts have 
been reported to have beneficial effects for the relief of diabetes [48,49]. In addition, 
currently available pharmacological agents for T2D exhibit a number of limitations, 
such as side effects and high rates of secondary failure. Thus, diabetic patients and 
healthcare professionals are considering complementary and alternative approaches 
[50-52]. Physicians now indicate that more than 75% of their patients use 
complementary and alternative medicine (CAM) therapies including herbs [53-55]. A 
survey conducted in 1997–1998 reported that about one-third of subjects with diabetes 
use CAM to treat their condition [56]. In other surveys of specific diabetic populations, 
39% of Navajo, two-thirds of Vietnamese, and 49% of a largely Hispanic population in 
South Texas used CAM [57-59]. While herbology is growing in popularity, some 
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surveys found that only 21% of people with diabetes who used any form of CAM 
talked to a healthcare professional about it [60]. In general, the scientific literature on 
the efficacy of herbal medicine in the treatment of diabetes is relatively sparse and 
heterogeneous. As growing numbers of patients are turning to alternative medicines, 
diabetes educators need to ask about the use of herbs and to be aware of their benefits 
and risks.  
1.3 GYNOSTEMMA PENTAPHYLLUM  
Gynostemma pentaphyllum Makino (Family Cucurbitaceae) (Giảo cổ lam – 
Vietnamese name or Jiaogulan – Chinese name) is a perennial creeping herb growing 
wild in the mountainous regions of Vietnam, Japan, China, and many other Asian 
countries. It is widely used in Vietnam and Southeast Asian countries as a herbal 
medicine, being beneficial for the prevention and treatment of diabetes. In addition to 
an anti-diabetic effect, GP extracts reportedly have various effects, such as cholesterol-
lowering and immunopotentiation, as well as antitumor and antioxidant effects [61-63]. 
Saponins, also known as gypenosides, are a large group of substances in GP extract. 
Currently, there are about 90 different gypenosides that have been isolated and 
characterized. Crude saponin fractions of GP extracts have shown to exert 
hypoglycemic and hypolipidemic effects in rats [62,63]. However, the actions of the 
functional component that is responsible for the anti-diabetic effect of GP extracts need 
to be elucidated. 
Our previous works on GP have revealed the anti-diabetic effect of GP extracts in 
normal rats, associated with a novel insulin-releasing gypenoside - phanoside [64,65]. 
Extracts of GP have been shown to reduce both hyperglycemia and hyperlipidemia in 
diabetic Zucker Fatty rats [66]. A recent experimental study demonstrated that ethanol 
extract of GP, produced in Vietnam, inhibited protein tyrosine phosphatase 1B (PTP-
1B) activity, which may lead to enhanced insulin sensitivity and thereby improved 
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glucose tolerance [67]. Therefore, it is highly relevant to use GP extracts to do research 
in subjects with diabetes.  
1.4 MODELS FOR ASSESSING ANTI-DIABETIC ACTIVITY 
There are some research techniques that are relevant to the study of diabetes, namely 
methods to assess insulin secretion and action, energy balance and body composition, 
and vascular structure. These techniques are applied to clinical investigations in 
humans; most approaches, with appropriate modifications, have also been used to study 
diabetes in animal models 
1.5 CLINICAL RESEARCH METHODS IN DIABETES 
Measurements of insulin action 
Insulin resistance refers to impairment to the physiological action of insulin. This is 
generally measured in terms of insulin’s glucose-lowering effect, which is convenient 
and easy to quantify. However, insulin has numerous other metabolic actions 
(antilipolytic, protein-anabolic) and also affects vascular and other tissues. Sensitivity 
to these different actions of insulin may vary considerably among individuals and also 
in different pathophysiological states. For example, subjects with T2D are relatively 
resistant to insulin’s hypoglycemic effect, but remain sensitive to its sodium-retaining 
action in the kidney. Thus identification of insulin resistance using any of the glucose-
based methods does not necessarily predict insensitivity to other actions of insulin. The 
modern methods that measure insulin sensitivity can be conveniently divided into three 
groups: 
- Steady-state techniques involve the continuously intravenous infusion of insulin 
with or without glucose, until a nearly constant plasma glucose concentration is 
reached. 
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- Dynamic methods use a bolus challenge of intravenous insulin allowing tissue 
glucose uptake to be derived from the changes in plasma glucose 
concentrations. 
- Basal-state methods calculate insulin resistance from simultaneous fasting 
plasma glucose and insulin concentrations.  
Steady-state methods 
All steady-state techniques exploit the principle that maximal insulin-stimulated 
glucose disposal, which occurs primarily in skeletal muscle, equates with the rate of 
glucose infusion required to maintain euglycemia under conditions of 
supraphysiological hyperinsulinemia 
- Euglycemic-hyperinsulinaemic clamp (EHC): this technique, developed to 
study kinetics and pioneered by DeFronzo and colleagues [68], is regarded as 
the gold standard method for determining insulin sensitivity. 
- Modification of the clamp technique: the EHC is a controlled and versatile 
technique that can be adapted to examine other aspects of insulin action. Using 
stepped increases in insulin infusion rates, together with somatostatin to 
suppress endogenous insulin secretion, the EHC has been used to construct a 
dose-response curve for insulin’s suppression of lipolysis and free fatty acid 
release in vivo. 
- Somatostatin-insulin-glucose infusion test (SIGIT): Patients initially are infused 
continuously with an intravenous infusion of somatostatin (270 µg/h) to 
suppress endogenous insulin and glucose secretion. Insulin and 20% glucose is 
then infused at doses of 0.4 mU/kg/min and 6 mg/kg/min, respectively. Plasma 
glucose and insulin are checked at zero, 30, 60, 90, 120 and 150 minutes. These 
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last 3 values are averaged to determine the steady-state plasma glucose level 
[69-71].  
- Measurement of hepatic glucose output (HGO): HGO can be estimated during 
steady-state conditions, in which it primarily provides an index of 
gluconeogenesis. HGO can be measured in the basal state and under conditions 
of hyperinsulinemia - giving an index of hepatic insulin action. 
- Insulin sensitivity tests: these methods involve the coinfusion of insulin and 
glucose at fixed doses until a steady-state is reached. 
Dynamic methods 
- Oral glucose tolerance test (OGTT): modification of the diagnostic OGTT has 
been employed to assess insulin sensitivity, as inferred from changes in insulin 
concentrations caused by the glucose challenge; however, the approach is 
invalid in diabetic patients, because of their impaired insulin secretion. 
- Insulin tolerance test: this test can be used to determine insulin sensitivity from 
the rate at which the blood glucose concentration falls following an intravenous 
injection of insulin.  
Basal-state methods 
- Homeostasis model assessment (HOMA): the widely used HOMA model, 
developed by Matthews and colleagues, uses fasting measurements of blood 
glucose and insulin concentrations to calculate indices of both insulin sensitivity 
and beta cell function [72]. The principle of HOMA is that blood glucose and 
insulin concentrations are related by feedback of glucose on beta cells to 
increase insulin secretion. For a given level of blood glucose, prevailing insulin 
levels therefore reflect both insulin sensitivity and beta cell function. 
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Evaluation of beta cell function 
Insulin secretory reserve can be assessed by several methods. To distinguish type 1 
(and other severe insulin-deficiency states) from type 2 diabetes, C-peptide 
concentrations can be measured after challenge with insulin secretagogues such as 
intravenous glucagon or a large carbohydrate load given orally. C-peptide is used in 
preference to insulin, because it is cleared more slowly and so provides a more reliable 
index of beta cell secretion.  
- Hyperglycemic clamp: the hyperglycemic clamp [68] can be used to measure 
insulin secretion under steady-state conditions of controlled hyperglycemia 
(≈10 mmol/L). The insulin response is biphasic, with an early peak, followed by 
a sustained rise. Indices of glucose-stimulated insulin secretion include the 
amplitude of the early peak, the final plasma insulin concentration achieved, or 
the absolute rise from baseline. These data can be expressed as percentages of 
levels achieved in normal subjects. Alternatively, systemic insulin delivery has 
been calculated as the product of the metabolic clearance rate (from EHC) and 
the total insulin response during the hyperglycemic clamp [68]. 
- Glutamic Acid Decarboxylase (GAD) and islet antigen 2 (IA-2) antibodies are 
commonly found in diabetes mellitus type 1. In making an early diagnosis for 
type 1 diabetes mellitus, GAD and IA-2 antibodies tests are used for differential 
diagnosis between latent autoimmune diabetes of adults (LADA) and type 2 
diabetes and may also be used for differential diagnosis of gestational diabetes, 
risk prediction in immediate family members for type 1 diabetes, as well as a 
tool to monitor prognosis of the clinical progression of type 1 diabetes [73]. 
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1.6 ANIMAL MODELS IN T2D RESEARCH 
Due to complex interactions among multiple susceptibility genes and between genetic 
and environmental factors, genetic analyses of diabetes are difficult to perform and the 
genetics of T2D are poorly understood in humans. Moreover, diabetes research in 
humans is impeded by obvious ethical considerations, because provocation of disease is 
strictly impermissible in man. Animal models of diabetes are therefore of great use in 
biomedical studies because they offer promise of new insights into human diabetes. 
Inbred animal models, in which the genetic background is homogeneous and 
environmental factors can be controlled, are therefore valuable in the genetic dissection 
of such a multi-factorial disease. Most of the available models are based on rodents 
because of their small size, short generation interval, easy availability and economic 
considerations. Spontaneously diabetic animals of T2D may be obtained from these 
animals which exhibit one or several genetic mutations transmitted from generation to 
generation (e.g., ob/ob mice, db/db mice), or by selection from non-diabetic outbred 
animals by repeated breeding over several generations e.g., Goto-Kakizaki (GK) rats 
and Tsumara Suzuki Obese Diabetes (TSOD) mice [74,75].  
Goto-Kakizaki (GK) rat 
The GK rat is a non-obese Wistar sub-strain which develops T2D early in life. The 
model was developed by Goto and Kakizaki at Tohoku University, Sendai, Japan in 
1975 [76]. The selections of breeding were based on selecting male and female Wistar 
rats with the highest glucose levels within the normal range, during a glucose tolerance 
test [76,77]. Repetition of the selective breeding over numerous generations resulted in 
the production of non-obese diabetic rats from Wistar rats. Colonies were then initiated 
with breeding pairs from Japan, including the Paris, Stockholm, Seattle and other 
colonies [78-81]. The Stockholm rat colony was initiated from progenitors delivered 
from the F40 generation of the original colony. Impaired insulin release appears in 
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early life and seems to be the primary defect [82]. Insulin resistance in skeletal muscle 
and liver is moderate and most likely secondary to hyperglycemia, at least in the 
muscle [82-84]. In GK rats, impaired glucose-stimulated insulin secretion has been 
demonstrated in vivo [78,85,86], in isolated pancreatic islets [79,87], and in the 
perfused isolated pancreas [78,79,82]. In GK rats from our colony, the pancreatic 
insulin content and density of beta cells are normal [82,88]. The defective insulin 
response to glucose in GK rats is accompanied by a number of abnormalities in islet 
glucose metabolism e.g. increases in glucose cycling and glucose utilization [79,87], 
and decreases in the activities of FAD-linked glycerol phosphate dehydrogenase, 
pyruvate carboxylase [79,89] and pyruvate dehydrogenase [90]. 
Glucose transporter 2 (GLUT 2) is found to be under-expressed, but not to the degree 
that could lead to the accounted impairment for the insulin release [91]. This hypothesis 
could be supported by the fact that glucokinase/hexokinase activities were found to be 
normal [79,92]. Also, glycolysis rates in GK rat islets are unchanged or increased 
compared with control islets [79,93,94]. Moreover, oxidation of glucose has been 
reported to be unchanged [79,87]. 
In GK rats, hepatic insulin resistance is accompanied by an increase in HGO in 
association with dysregulation of hepatic fructose-2-6-bisphosphate. Hepatic insulin 
resistance was also characterized by decreased insulin receptor number but normal 
tyrosine kinase activity [83]. 
In the skeletal muscle, defective activation of glucose accumulation into glycogen, 
possibly due to the chronic activation of protein kinase C [95,96], has been suggested to 
contribute to insulin resistance and hyperglycemia in GK rats. Additionally, defective 
post-receptor signaling was characterized by alterations in insulin-stimulated glucose 
transport and PI3K-activated Akt kinase [84]. 
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2 AIMS  
The overall aim of this thesis is to investigate the anti-diabetic effect and safety of the 
traditional Vietnamese herb Gynostemma pentaphyllum (GP) extract (tea) in type 2 
diabetic patients (T2D) and identify the major mechanisms of action of GP in patients 
with T2D, as well as in Goto-Kakizaki (GK) rats. 
Specific aims for the four papers are as follows: 
I. To investigate the anti-diabetic effect of GP tea in drug-naïve T2D patients. 
II. To study the anti-diabetic effect of GP tea as add-on therapy with 
sulfonylureas in drug-naïve T2D patients. 
III. To evaluate the effect of GP tea on insulin sensitivity in drug-naïve T2D 
patients. 
IV. To explore the effect of GP tea on hepatic glucose output in spontaneously 
type 2 diabetic GK rats. 
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3 MATERIALS AND METHODS  
 
3.1 MEDICATION 
The medication was provided in the form of GP tea at a dose of 6g/day (3g/packet, 
twice a day). The whole plants of Gynostemma pentaphyllum Makino-Cucurbitaceae 
were collected from the Hoa Binh province, in the north of Vietnam, and identified by 
Professor Pham Thanh Ky, Department of Material Medica, Hanoi College of 
Pharmacy. The production of GP tea included two stages. The first stage was to 
confirm authenticated GP plants which were compared with the voucher specimen 
(HN-0152) deposited in the herbarium at the Department of Material Medica, Hanoi 
College of Pharmacy. The second stage was to produce the GP tea as specified. Briefly, 
the process included extraction of the authenticated GP plants for 2h in boiling water, 
and with a following precipitation of impurities by adding concentrated 70% ethanol. 
The 70% ethanol was then removed by distillation at low pressure, and impurities were 
removed by filtration. Thereafter, the tea was inspected as a semi-finished brown 
powder with the typical odour of GP tea. This powder had a humidity of approximately 
6.7%, and could be dissolved in water to produce a brown liquid with a sweet-bitter 
flavour. The tea contained flavonoids, as shown by a positive cyanidin reaction with the 
base FeCl3 (5%) [97,98], and furthermore about 18% saponins, as indicated by a 
positive foaming test [97,98]. Thus, the standardization of the GP tea included 
confirmation of its typical odour, state and sweet-bitter flavour, approximately 7% in 
humidity, and positive reactions in the flavonoid (cyanidin reaction) and saponin 
(foaming) tests. The placebo extract was green tea extract (tea) (Camellia sinensis), 
which was supplied at the same dose and was similar to the GP tea in shape and 
packaging. After grinding of the resulting GP and placebo material into a powder to 
form soluble particles, the powder was packed in tin foil packets (6x5 cm) by an 
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automatic packing machine. Each packet contained 3 g of powder, and 10 packets were 
packed in one box to be distributed to the patients. Both GP and placebo tea were easily 
dissolved in 60 mls water (room temperature) and taken 30 minutes prior to breakfast 
and dinner. 
3.2 SUBJECTS 
Patients for Paper I, II and III 
The studies were implemented on newly-diagnosed T2D patients. All subjects were 
recruited from outpatients at the National Institute of Gerontology and some district 
hospitals in Hanoi. The treatment options and possibility of beneficial effects and risks 
of the treatment were explained to newly-diagnosed patients with T2D. The treatment 
option was left to the subject’s discretion. Consecutive patients were enrolled into the 
study. Written informed consent was obtained from all subjects. The study protocol 
was approved by the research ethics board at Hanoi Medical University, Hanoi, 
Vietnam and the Regional Ethics Committee at the Karolinska Institute, Stockholm, 
Sweden. 
Inclusion criteria were: 1) newly-diagnosed patients with T2D according to WHO 
criteria [99] were recruited from outpatients at the National Institute of Gerontology 
and some district hospitals in Hanoi, Vietnam; 2) age from 40 to 70 years old, 3) anti-
diabetic drug naïve; 4) mean (of two) fasting plasma glucose (FPG) measurements 
from 9 to 14 mmol/L; and 5) glycosylated hemoglobin (HbA1C) from 9 to 13%.  
Exclusion criteria were: 1) previous pharmacological treatment for diabetes, 2) chronic 
complications related to type 2 diabetes, 3) smoking subjects, 4) pregnancy or lactation 
and 5) increased titres of GAD and IA-2 antibodies. 
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Evaluation at baseline included detailed medical history and examination, fasting and 
oral glucose tolerance test, HbA1C, liver and renal function tests, fasting lipid profile, 
and plasma insulin and C-peptide levels. 
Animals for Paper IV 
Diabetic Goto-Kakizaki (GK) rats (200-300g), originating from Wistar rats, were bred 
in our department. The animals were kept at 22˚C on a 12-hour light-dark cycle (6 a.m 
and 6 p.m) with free access to food and water during GP treatment (see below) and 
before being anesthetized for liver perfusion. The study was approved by the 
Laboratory Animal Ethics Committee of the Karolinska Institute (N367/08, N72/08). 
3.3 METHODS FOR PATIENTS WITH T2D 
The study used a randomized, placebo-controlled, double-blind design for Papers I and 
II, and a cross-over design for Paper III. Group assignment of patients was blinded for 
both the main investigator and other investigators performing outcome analyses by use 
of a coding system, where the codes were kept by the independent allocator and 
revealed only after completing treatment periods and analyses. The patients were 
instructed to follow the diet as always recommended for newly diagnosed T2D patients. 
The patients were also told to walk 30 minutes a day and at least three days a week 
during the trial. This was reinforced at each follow-up visit every week. All patients 
were treated on an out-patient basis with individual medical records and were provided 
tea for a week; all tea bags were counted out at each visit. The subjects were 
encouraged to call the physicians at any time if they had problems. 
Paper I 
The design of the study is shown in Figure 1a. After screening by the main investigator, 
the selected patients were randomly assigned by another, independent allocator by use 
of numbered containers into 2 groups, matched by sex: group A and group B received 
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GP tea and placebo tea, respectively, in a divided dose (twice a day, 30 minutes before 
breakfast and dinner).  
Figure 1a. 
  
Paper II 
The protocol of this clinical trial is presented in Figure 1b. After screening, the selected 
subjects received gliclazide modified-release preparation 30 mg daily as a single dose, 
and entered a 4-week run-in period of reinforcement of lifestyle education, followed by 
concealed randomization. After the four week-run in, all selected patients were 
randomly assigned by another, independent allocator by use of numbered containers 
into 2 groups, matched by age, sex and HbA1C: group A and group B received GP tea 
and placebo tea, respectively, in a divided dose (twice a day, 30 minutes before 
breakfast and dinner).  
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Figure 1b. 
 
Paper III 
The protocol of this clinical trial is presented in Figure 1c. After screening by the main 
investigator, the selected patients were randomly assigned by another, independent 
allocator by use of numbered containers into two groups, matched by age, sex, fasting 
plasma glucose and HbA1C: group A and group B received GP tea and placebo tea, 
respectively, 6 g daily in a divided dose (twice a day, 30 minutes before breakfast and 
dinner). After a two-week wash-out period on non-tea therapy, the patients were 
switched to another four weeks of 6 g GP tea/day (group B) and placebo-tea (group A). 
At the end of both four-week periods of treatment with GP or placebo tea, all patients 
underwent a somatostatin-insulin-glucose infusion test. 
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Figure 1c.  
 
Somatostatin-Insulin-Glucose Infusion Test (SIGIT) (Paper III) 
All subjects participated in the SIGIT, performed at 8am after an 8-10h overnight fast 
with only tap water allowed ad libitum. The SIGIT, lasting 150 minutes, was conducted 
as described earlier [70,71]. Briefly, an i.v cannula (Exeflon, Exelint, Los Angeles, 
California, USA) was inserted into an antecubital vein for infusion of all test 
substances. A second cannula was inserted into a wrist vein contra-laterally to the 
infusion site for blood sampling. Each subject was given a 150 minute intravenous 
infusion of somatostatin (270 µg/h; Somatosan, Wasserburger Arzneimittelwerk 
GmbH, Wasserburg, Germany), insulin (0.4 mU/kg/min; Actrapid HM, Novo Nordisk, 
Denmark) and glucose (6 mg/kg/min; in a 20% solution). Ten ml blood of each patient 
was added to the mixture to prevent absorption of insulin and somatostatin onto the 
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glass surface. Plasma glucose and insulin were measured at 0, 30, 60, 90, 120 and 150 
minutes. Somatostatin was used to suppress endogenous insulin release, thereby 
allowing an estimation of sensitivity to exogenously administered insulin by measuring 
blood glucose values at 90, 120 and 150 minutes of the test (SIGIT mean). Since 
similar steady-state plasma insulin levels are achieved in all subjects, this test allows us 
to compare the ability of the recruited subjects to dispose of identical glucose loads 
under the same insulin stimulus. Therefore, the mean of several plasma glucose 
concentrations measured during the steady-state period from 90 to 150 minutes is a 
measure of efficiency of insulin-mediated glucose utilization, i.e., insulin sensitivity. 
Biochemical and anthropometric analyses 
Blood samples of fasting subjects were taken before, during (every week  or second 
week for 10-12 weeks), and after the treatment for measurement of plasma glucose, 
HbA1C, liver enzymes (ALT, AST), creatinine, lipid profiles, glucagon, cortisol, insulin 
and C-peptide levels. Serum samples were obtained by centrifugation and stored at 
minus 20ºC pending for assay. Analysis of glucose concentration of each sample was 
done by enzymatic colorimetric test, GOD-PAP in a glucose analyzer (Autolab 
Instrument, Boehringer Mannheim, Germany, wave-length Hg 546 nm). HbA1C was 
measured with a BIO-RAD D-10TM (Bio-Rad, Strasbourg, Schiltigheim, France). The 
insulin concentration was measured by insulin radioimmunoassay (RIA), using our 
own antibodies, human insulin as a standard, and charcoal addition to separate 
antibody-bound and free insulin [100], glucagon was determined by RIA (Euro-
Diagnostica AB, Medeon, Malmö, Sweden), and cortisol was analyzed by Cortisol RIA 
DSL-2000 (Cherwell Innovation Centre, Upper Heyford, Oxon, UK). C-peptide was 
measured by human C-peptide RIA kit (HCP-20K, Millipore, 6 Research Park Drive, 
St. Charles, Missouri 63304 USA). Oral glucose tolerance tests (OGTT) (75g glucose) 
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were performed four times for Paper I, three times at baseline, after four and twelve 
weeks for Paper II, and at baseline to confirm the diabetic diagnosis for Paper III. 
Venous blood samples were drawn before, 30 and 120 minutes after glucose intake. 
The Homeostasis Model Assessment (HOMA) was used to assess insulin sensitivity 
and beta cell function, based on fasting insulin and glucose levels and according to 
published algorithms: HOMA insulin resistance (HOMA-IR) = (insulin x 
glucose)/22.5, and HOMA beta cell function (HOMA-β) = 20 x insulin/(glucose -3.5) 
[72]. Body weight, body mass index (BMI), waist and hip circumference, blood 
pressure, and registered adverse effects were noted in medical records during the visits. 
3.4 METHODS FOR GK RATS 
Oral administration of GP and placebo tea 
GP and placebo tea were given to unanesthetized male GK rats by gavage through an 
enteral feeding tube (polyvinyl chloride, sterile VYCON, Lab. Pharmaceutiques Vycon, 
Ecouen, France) connected to a syringe with the solutions. The GK rats were divided 
into two groups in each experiment; 800 mg/kg of GP tea or placebo tea were given 
twice a day at 9:00 and 15:00 for three days or three weeks. 
Plasma glucose (PG) measurement 
Blood samples for determination of glucose (about 20µl/sample) were taken after a 
small tail incision. PG levels were monitored by the glucose dehydrogenase method 
(Accu-Check, Aviva) every 2 days before the oral administration of GP or placebo tea. 
Intraperitoneal Glucose Tolerance Test (IPGTT) and Intraperitoneal Pyruvate 
Tolerance Test (IPPTT) 
IPGTT and IPPTT were carried out in overnight fasted GK rats. PG concentrations 
were obtained at 0, 15, 30, 60, and 120 minutes after an intraperitoneal (i.p.) injection 
 24 
of glucose (2 mg/g body weight; Glukos APL 500 mg/ml) or pyruvate (2 mg/g body 
weight; sodium pyruvate, SIGMA), respectively.  
Subcutaneous (s.c) insulin tolerance test (SCITT) 
For the SCITT, insulin was injected s.c. at a dose of 0.5 U/kg and PG levels were 
measured in fasted GK rats before the injection of insulin (0 min) and every 15 minutes 
for 2 hours and then every 30 minutes for another 2 hours. 
Isolation and perfusion of GK rat liver for determination of hepatic glucose 
output (HGO) 
Liver perfusions were started between 10 a.m. and noon. The rats were anesthetized 
with an i.p. injection of ketamine (60-70 µg/g body weight; Pfizer AB, Täby, Sweden). 
Livers were perfused in situ without recirculation in a 37°C cabinet via the portal vein 
using Krebs-Henseleit bicarbonate buffer (KRB), pH 7.4, which was equilibrated with 
95% O2 and 5% CO2. The perfusion pressure was kept constant with a flow rate of 3.0-
4.0 ml/min/g liver. 
Adrenaline (Merck AB NM, Stockholm, Sweden) was diluted into the perfusion 
medium (KRB) to a final concentration of 50 nmol/L. Livers were perfused for 8-18 
minutes. In rats treated for three days, livers were perfused with KRB for eight minutes. 
In rats treated for three weeks, the first eight minutes of perfusion with KRB only was 
followed by addition of adrenalin (50 nmol/L) in KRB for 10 minutes. Samples of the 
perfusate were taken at 2-minute intervals from the inferior caval vein during perfusion, 
and their glucose levels were measured by the glucose oxidase method using a glucose 
analyzer (Yellow Springs Instruments). Hepatic glucose output was calculated using 
the mean glucose concentration in relation to flow rate and hepatic dry weight. These 
livers were not used for any other measurements. 
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Hepatic glycogen content 
Liver homogenates were extracted in 80% ethanol to remove glucose. An aliquot of 
each homogenate was mixed with amyloglucosidase (Roche Applied Science) and 
incubated at 60°C for 15 minutes to degrade glycogen into glucose residuals. The 
samples were diluted and incubated with 1 ml Glucose Assay Reagent (o-Dianisidine 
Reagent + Glucose Oxidase /Peroxidase Reagent, Sigma-Aldrich) at 37°C for 30 
minutes, followed by the addition of 1 ml 12N H2SO4 to stop the reaction. The 
absorbance of glucose was read at 540 nm. In parallel, different concentrations of rabbit 
liver glycogen type III (Sigma-Aldrich) were treated as the samples and used as a 
standard curve.  
Hepatic glycogen synthase (GS) activity  
GS was determined by a method based on the incorporation of 14C-labelled uridine 
diphosphate-glucose into glycogen. The active form of GS (the form which is activated 
by insulin) was measured at a low concentration of glucose-6-phosphate (0.3 mm) and 
the total GS at a high concentration (6.0 mm). 
3.5 STATISTICAL ANALYSIS:  
Results are expressed as means ± SD in Papers I, II and III, and means ± SEM in Paper 
IV. Paired t-tests and ANOVA were used to analyze data in the same group before and 
after treatment, with Bonferroni correction for multiple testing. The unpaired sample t-
test was used for normally distributed variables to compare differences in mean change 
between the treatment group and the control group (SPSS version 12.0 in Papers I, 
SPSS version 16.0 in Papers II and III, Sigmaplot 2001 in Paper IV). Differences were 
considered significant if the p-value was below 0.05. 
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4 RESULTS 
 
4.1 BASELINE CHARACTERISTICS OF THE PATIENTS IN 3 TRIALS 
(PAPERS I, II, III) 
In Paper I, the baseline evaluations of all selected T2D patients revealed that there were 
no statistically significant differences between the treatment group and the control 
group on age, gender, systolic and diastolic blood pressure (SBP and DBP), body 
weight, BMI, waist, hip circumference, FPG, and HbA1C (Table 1a). All patients were 
compliant with the treatment protocol and completed the study. There were no adverse 
effects, such as gastrointestinal (nausea or vomiting) and hypoglycemic symptoms, 
from either GP tea or placebo tea during the research period. Body weights and BMI 
values at the end of the study were not significantly different from those at the baseline 
value.  
In Paper II, after a 4-week treatment with SU, FPG was significantly decreased from 
11.4 ± 1.3 to 9.3 ± 1.3 mmol/L (n = 25, p < 0.001). A similar decrement was observed 
with HbA1C from 9.9 ± 1.0 to 8.9 ± 0.7% (p < 0.001). Increases in C-peptide and insulin 
levels, and improvements of lipid profile were also found. At the fourth week, 
evaluations of all selected T2D patients revealed no statistically significant differences 
between groups allotted to treatment with GP and placebo tea regarding age, gender, 
SBP and DBP, body weight, BMI, waist, hip circumference, FPG, and HbA1C (Table 
1b). All patients were compliant with the treatment protocol. 
In Paper III, the baseline characteristics of the patients receiving GP treatment initially 
did not differ significantly from those starting with placebo and vice versa at week 6, 
after two weeks of wash-out (Table 1c). There were no statistically significant 
differences between the groups regarding age, gender, SBP and DBP, body weight, 
BMI, waist, hip circumference, FPG, and HbA1C. 
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Table 1a. Baseline clinical characteristics and laboratory findings of the patients  
 GP group Control group 
N 12 12 
Age (years) 63.5 ± 6.5 57.2 ± 8.2 
Sex (Male:Female) 8:4 9:3 
Body weight (kg) 61.1 ± 10.0 57.6 ± 10.6 
BMI (kg/m2) 24.0 ± 2.3 23.0 ± 2.6 
Waist  90.3 ± 6.7 88.3± 8.9 
Hip  99.3 ± 6.4 98.2 ± 6.0 
SBP (mm Hg) 120 ± 10.0 117 ± 10.0 
DBP (mm Hg) 78 ± 4.5 75 ± 6.8 
FPG (mmol/L) 10.0 ± 2.2 9.3 ± 2.3 
FPI (pmol/L) 94.4 ± 31.2 79.5 ± 27.8 
HbA1C (%)  9.4 ± 2.0 8.2 ± 1.6 
Cholesterol (mmol/L) 4.9 ± 1.3 4.8 ± 1.2a 
Triglyceride (mmol/L) 2.8 ± 1.5 2.6 ± 1.8a 
HDL-cholesterol (mmol/L) 1.0 ± 0.2 1.0 ± 0.3a 
LDL-cholesterol (mmol/L) 3.1 ± 0.9 2.7 ± 0.9a 
Results are means ± SD. a n=11, after removal of one patient with an extreme 
triglyceride value (22 mmol/l). SBP = Systolic Blood Pressure, DBS = Diastolic Blood 
Pressure, FPG = Fasting Plasma Glucose, FPI = Fasting Plasma Insulin 
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Table 1b. Clinical characteristics and laboratory findings of the patients at 
baseline and after 4 weeks 
 
GP group Control group 
Baseline After 4 weeks Baseline After 4 week 
N 12 12 13 13 
Age (years) 55.6 ± 9.9 55.6 ± 9.9 54.5 ± 8.4 54.5 ± 8.4 
Sex (Male:Female) 7:5 7:5 8:5 8:5 
Body weight (kg) 54.8 ± 6.8 54.9 ± 6.9 55.3 ± 11.9 55.3 ± 11.4 
BMI (kg/m2) 21.7 ± 2.7 21.8 ± 2.7 22.5 ± 4.4 22.5 ± 4.2 
Waist  86.0 ± 5.8 85.8 ± 5.9 87.1 ± 11.4 87.3 ± 11.5 
Hip  95.8 ± 3.8 95.3 ± 4.3 97.9 ± 8.5 97.3 ± 8.5 
SBP (mm Hg) 122.5 ± 8.7 123.5 ± 9.1 119.2 ± 6.4 119.2 ± 6.4 
DBP (mm Hg) 79.6 ± 5.4 79.6 ± 5.3 77.7 ± 4.2 76.2 ± 5.1 
FPG (mmol/L) 11.6 ± 1.1 9.6 ± 1.6 11.1± 1.5 9.0 ± 1.0 
FPI (pmol/L) 96.1 ± 33.0 120.0 ± 42.0 101.4 ± 34.2 131.4 ± 67.2 
HbA1C (%)  9.9 ± 1.0 9.0 ± 0.7 9.9 ± 1.1 8.8 ± 0.6 
C-peptide (ng/mL) 0.9 ± 0.5 1.7 ± 0.7 0.8 ± 0.6 1.5 ± 0.8 
30-minute C-peptide 
(ng/mL) 
1.4 ± 1.0 2.2 ± 1.3 1.5 ± 1.4 2.9 ± 1.3 
Cholesterol (mmol/L) 5.5 ± 1.3 4.8 ± 1.1 4.8 ± 1.1 4.3 ± 0.8 
Triglyceride (mmol/L) 3.2 ± 2.5 2.4 ± 1.5 2.7 ± 2.0 2.0 ± 1.2 
HDL-cholesterol (mmol/L) 1.3 ± 0.3 1.3 ± 0.4 1.2 ± 0.2 1.1 ± 0.2 
LDL-cholesterol (mmol/L) 3.0 ± 0.8 2.8 ± 0.9 2.9 ± 0.9 2.3 ± 0.6 
Results are means ± SD, SBP = Systolic Blood Pressure, DBS = Diastolic Blood 
Pressure, FPG = Fasting Plasma Glucose, FPI = Fasting Plasma Insulin
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Table 1c. Clinical characteristics and laboratory findings of the patients  
 
 
Group A (GP-Placebo tea) Group B (Placebo tea - GP) 
Baseline Week 6 Baseline Week 6 
N 8 8 8 8 
Age (years) 58.8 ± 5.9 58.8 ± 5.9 58.1 ± 6.6 58.1 ± 6.6 
Sex (Male:Female) 5:3 5:3 5:3 5:3 
Body weight (kg) 58.6 ± 5.3 58.8 ± 5.4 56.8 ± 4.9 57.1 ± 5.0 
BMI (kg/m2) 23.3 ± 1.9 23.4 ± 2.0 22.6 ± 1.8 22.7 ± 1.9 
Waist  85.8 ± 6.2 85.4 ± 5.8 81.0 ± 6.1 81.9 ± 6.0 
Hip  94.4 ± 3.5 94.1 ± 3.3 91.8 ± 4.2 91.6 ± 4.0 
SBP  (mm Hg) 119.4 ± 10.2 119.4 ± 11.5 118.2 ± 8.3 118.5 ± 7.9 
DBS  (mm Hg) 74.4 ± 5.0 74.4 ± 4.9 76.3 ± 4.2 76.3 ± 5.1 
FPG (mmol/L) 8.3 ± 0.8 7.4 ± 0.6 8.4 ± 0.7 8.0 ± 1.0 
FPI (pmol/L) 141.0 ± 38.2 132.0 ± 109.2 113.2 ± 65.3 122.9 ± 78.5 
HbA1C (%)  8.1 ± 0.9  8.1 ± 0.7  
Cholesterol (mmol/L) 5.4 ± 0.8 5.4 ± 1.0 5.0 ± 0.9 5.4 ± 1.2 a 
Triglyceride (mmol/L) 2.2 ± 1.5 2.1 ± 0.9 2.1 ± 1.1 2.7 ± 1.3a 
HDL-cholesterol (mmol/L) 1.5 ± 1.0 1.2 ± 0.2 1.1 ± 0.2 1.1 ± 0.2 a 
LDL-cholesterol (mmol/L) 3.3 ± 1.2 3.3 ± 1.0 3.0 ± 0.7 3.0 ± 0.8 a 
Results are means ± SD of sixteen patients. a n=7, after removal of one patient with an 
extreme triglyceride value (12 mmol/l). SBP = Systolic Blood Pressure, DBS = 
Diastolic Blood Pressure, FPG = Fasting Plasma Glucose, FPI = Fasting Plasma Insulin 
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4.2 EFFECTS OF GP TEA ON GLUCOSE REGULATION 
In Paper I, after 12-weeks treatment, the FPG in the GP group decreased significantly 
(from 10.0 ± 2.2 to 7.0 ± 1.4 mmol/L, p < 0.001), while the levels of FPG in the control 
group did not change significantly (Figure 2a). Thus, at the end of treatment period, 
FPG had decreased 3.0 ± 1.8 mmol/L in the GP tea group, as compared to 0.6 ± 2.2 
mmol/L in the control group (p < 0.01). There was no change in fasting plasma insulin 
levels between the groups. Therapy with GP tea did not decrease 30 and 120 minute 
OGTT post-load glucose values significantly. The HbA1C values decreased from 9.4 ± 
2.0 to 7.4 ± 1.0% in the GP tea group and from 8.2 ± 1.6 to 8.1 ± 1.3 in the control 
group. Thus, the decrement was significantly larger in the intervention group than in 
the control group (2.0 ± 1.3 versus 0.2 ± 0.5 %, p < 0.001). 
Change in HOMA-IR between baseline and the twelfth week indicated that insulin 
resistance decreased significantly in the GP group (-2.1 ± 3.0) compared with that (+1.1 
± 3.3) in the control group (p < 0.05), but there were no significant changes in   
HOMA-β during 12 weeks (Table 2). 
In Paper II, FPG was not different between groups after four weeks treatment with SU, 
but was significantly decreased after six weeks of add-on GP tea with SU (p < 0.001) 
(Figure 2b). At the end of the treatment course, the value of FPG decreased by 2.9 ± 1.7 
mmol/L to a level of 6.8 ± 0.4 mmol/L (p < 0.001) in the GP tea group. The levels of 
FPG in the control group were slightly reduced (0.9 ± 0.6 mmol/L, p<0.001 vs. 
reduction in GP group) at the end of the treatment period to a level of 8.1 ± 1 mmol/L. 
Therapy with GP tea also significantly decreased 30 and 120 minute OGTT post-load 
glucose values. The HbA1C values decreased from 9.0 ± 0.7 to 7.0 ± 0.7% in the GP 
group, and from 8.8 ± 0.6 to 8.1 ± 0.6% in the placebo group. Thus, the decrement was 
significantly larger in the GP group than that in the control group (2.0 ± 0.9 versus    
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0.7 ± 0.5 % units, p < 0.001) (Table 3). The glycometabolic improvements were 
achieved without any major change of circulating insulin and C-peptide levels. 
 
Table 2- Change in HOMA-IR and HOMA-β 
 
 HOMA-IR HOMA-β 
 GP group 
(n=11) 
Control group 
(n=12) 
p 
 
GP group 
(n=11) 
Control group 
(n=12) 
p 
Baseline 6.96 ± 2.32 5.32 ± 1.91 0.077 54.79 ± 32.51 54.79 ± 32.28 1 
After 12-week  4.82 ± 2.64 6.89 ± 3.8 0.236 50.36 ± 30.65 69.6 ± 53.03 0.305 
Change (0-12 weeks) -2.14 ± 3.05 1.1 ± 3.27 0.023 - 4.43 ± 26.17 14.82 ± 37.2 0.17 
 
Results are means ± SD. Insulin value missing in one patients of GP group 
 
In Paper III, treatment with GP tea compared to placebo induced no differences in 
fasting plasma insulin (FPI) but resulted in lower FPG (p < 0.001; Table 4). Following 
treatment with GP tea, the FPG decreased by 1.9 ± 1.0 mmol/L, while the levels of 
FPG in the placebo treatment were not significantly reduced (-0.2 ± 1.5 mmol/L, p < 
0.001). These effects were reversed after exchanging treatment (Figure 2c) and the 
glycometabolic improvements were achieved without any major change of circulating 
insulin levels (Table 4, Figure 2c). 
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Figure 2a.  Fasting plasma glucose (mmol/L) and insulin (pmol/L) levels in GP (A and 
C) and control (B and D, respectively) groups. Means ± SD (n=12 in each group except 
n=11 for insulin in GP group). 
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Figure 2b.  Fasting plasma glucose (mmol/L) and insulin (pmol/L) levels in GP (A and 
C) and control (B and D, respectively) groups after adding GP or placebo tea. Means ± 
SD (n=12 in GP group and n=13 in control group). 
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Table 3. Changes in HbA1C from week 4 to week 12 
HbA1C (%) 
GP tea group 
n=12 
Placebo group 
n=13 
p 
Week  4 9.0 ± 0.7 8.8 ± 0.6 0.516 
Week  12 7.0 ± 0.7 8.1 ± 0.6 < 0.001 
Change (4-12 weeks) -2.0 ± 0.9 -0.7 ± 0.5 < 0.001 
   Results are mean ± SD 
The mean steady-state plasma insulin levels and plasma glucose responses of the two 
groups during the SIGIT study are given in Table 4. The steady-state plasma insulin 
(SSPI) response clearly indicates that similar plasma levels of exogenous insulin were 
attained as a result of the infusion in all subjects. In contrast, the mean steady-state 
plasma glucose (SSPG) responses were markedly decreased after GP extract treatment 
(p < 0.01), indicating improved insulin sensitivity. 
Changes in body weight and other parameters 
There were no significant differences within or between groups regarding changes in 
serum triglyceride, total cholesterol, HDL and LDL cholesterol levels. Similarly, no 
significant changes in the plasma levels of AST, ALT, creatinine, BUN were detected 
during the study. Neither the GP tea -treated nor placebo groups experienced any acute 
adverse effect such as gastrointestinal, diarrhea and hypoglycemic symptoms during the 
research period, and all patients were compliant with the treatment protocol and 
completed the study. 
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Table 4. Plasma glucose, insulin levels and SIGIT mean in two kinds of treatment  
 GP treatment Placebo treatment p 
FPG before treatment (mmol/L) 8.2 ± 0.9 7.9 ± 0.8 0.385 
FPG after treatment (mmol/L) 6.3 ± 0.8 7.7 ± 1.9 0.039 
Change in FPG (mmol/L) -1.9 ± 1.0 -0.2 ± 1.5 < 0.001 
SSPG (SIGIT mean) (mmol/L) 12.5 ± 3.2 16.2 ± 4.1 < 0.01 
FPI before treatment (pmol/L) 123.6 ± 59.7 122.2 ± 79.9 0.971 
FPI after treatment (pmol/L) 130.6 ± 81.3 120.1 ± 106.3 0.773 
Change in FPI (pmol/L) -0.2 ± 7.8 -0.3 ± 9.8 0.984 
SSPI (pmol/L) 223.6 ± 91.0 218.1 ± 104.9 0.696 
Results are means ± SD of sixteen patients in each treatment. FPG = Fasting Plasma 
Glucose, FPI = Fasting Plasma Insulin, SSPG: steady-state plasma glucose; SSPI: 
steady-state plasma insulin. 
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Figure 2c.  Fasting plasma glucose (mmol/L) and insulin (pmol/L) levels in Group A (a 
and c) and Group B (b and d). Means ± SD (n = 8 in each group). 
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4.3 EFFECT OF GP EXTRACT ON PG IN GK RATS  
The three-day treatment of GK rats with 800 mg/kg GP tea, or placebo tea, given orally 
twice a day had no significant effect on PG levels (from 9.9 ± 1.2 to 8.9 ± 0.6 mmol/L 
in GP treated, and from 8.5 ± 0.4 to 8.6 ± 0.3mmol/L in placebo treated rats). In the 
three-week treatment, the PG concentrations were reduced significantly in GP treated 
rats from 9.8 ± 0.6 to 6.8 ± 0.4 mmol/L (p = 0.027), while in the placebo rats, PG levels 
were slightly but not significantly decreased from 8.8 ± 0.8 to 7.5 ± 0.3 mmol/L. 
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Effect of GP tea on IPGTT, SCITT and IPPTT in GK rats   
In the IPGTT, the baseline glucose tolerance test (day 0) was similar in both groups, the 
areas under the glucose curves (AUCs) during 120 min (0-120 min) being 1995.1 ± 
102.2 vs. 2029.5 ± 135.1 mmol/L, (p = 0.843). However, after the three-week treatment 
with GP tea, the glucose tolerance was significantly improved as compared to that in 
the placebo group, with AUCs 1149.6 ± 200.0 vs. 1727.9 ± 95.5 mmol/L, respectively 
(p < 0.05; Figure 3). After the three-week treatment, the PG concentrations in rats 
administered with s.c. insulin (0.5 U/kg, SCITT) were reduced similarly in both groups, 
AUCs (0-240 min) (-149.7 ± 71.8 vs. -110.4 ± 65.1 mmol/L, p = 0.696; Figure 4). In 
the IPPTT, there were no significant differences in the total glucose responses between 
the two groups, AUCs (0-120 min) (1137.7 ± 67.8 vs. 1240.1 ± 103.6 mmol/L; p = 
0.432; Figure 5). However, when analysing the glucose response from minute 15 to 
minute 120, the AUC (15-120 min) was significantly lower in the GP group (415.5 ± 
68.0 vs. 641.5 ± 41.8 mmol/L; p < 0.05). 
 
Figure 3. Mean of plasma glucose levels in the intraperitoneal glucose tolerance test 
after the three-week treatment. 
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Figure 4. Mean of plasma glucose levels in the subcutaneous insulin tolerance test after 
the three-week treatment. 
 
Figure 5. Mean of plasma glucose levels in intraperitoneal pyruvate tolerance test after 
the three-week treatment. 
 
 
Effect of GP tea on HGO levels in GK rats 
After the three-day treatment with GP tea, basal HGO was 20% lower in comparison 
with that in the placebo group (28.8 ± 6.5 vs. 36.1 ± 11.6 µmol/min). After three weeks, 
the basal HGO in GP treated rats was 27% lower (25.7 ± 5.9 vs. 35.1 ± 5.8 µmol/min in 
treated and placebo groups, respectively), but these differences were not statistically 
significant. However, in the three-week treated GK rats, AUCs for HGO during 18 
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minutes (0-18 min) was significantly decreased, as compared with the placebo rats 
(302.8 ± 36.5 vs. 423.5 ± 44.7 µmol/min, p = 0.05; Figure 6). In addition, infusion of 
50 nmol/L adrenaline beginning after 8 min of perfusion (8-18 min, adjusted to the 8 
min of perfusion) did increase the HGO in all rats but the response to adrenaline tended 
to be lower in the treated rats compared to the placebo rats (27.5 ± 8.9 vs. 61.0 ± 17.5 
µmol/min, p = 0.114). 
 
Figure 6. Mean of hepatic glucose output after the three-week treatment, (basal 
perfusion 0-8 min, and addition of 50 nM adrenaline 8-18 min). 
 
 
Effect of GP tea on hepatic glycogen content and GS activity in liver of GK rats  
The three-week treatment with GP tea significantly reduced the hepatic glycogen 
content, as compared to the placebo group (18.3 ± 4.6 vs. 35.6 ± 2.9 mg/g liver, 
respectively, p < 0.007). The hepatic glycogen synthase activity did not differ in the 
group treated with GP tea (40.5 ± 6.3 percent), compared to that in the placebo group 
(35.9 ± 6.2 percent).  
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5 DISCUSSION 
The main findings of our studies were that GP tea exerted a significant anti-diabetic 
effect, and that this was accounted for by enhanced insulin sensitivity.  
The placebo group and the GP group did not differ in baseline characteristics and 
diabetic parameters (drug naïve T2D, HbA1C, FPG) in Papers I, II, and III. The GP tea 
was mainly responsible for the reduction in glucose levels because all patients received 
similar diet and exercise therapies, with only a minor effect on FPG in the control 
group. Green tea (Camellia sinensis) was reported to induce anti-hyperglycemic effects 
in mice and stretozotocin-diabetic rats [101,102], but there is little evidence that it 
improves glycemic control substantially in human T2D [102,103]. 
In Paper I, during 12 weeks of the therapy with GP tea, HbA1C levels decreased 
significantly by approximately 2%-units, while in control subjects using placebo HbA1C 
levels did not change. In Paper II, these results were reaffirmed by improving glycemic 
control in patients treated with SU who received the addition of GP tea, as compared to 
patients on SU therapy alone. Add-on GP tea therapy with SU lead to decreases in 
HbA1C of approximately 2%-units, and in FPG of nearly 3 mmol/L over 8 weeks. This 
HbA1C lowering effect was clearly comparable with other oral anti-diabetic agents used 
as monotherapy, e.g. metformin with a 1.4% to 2% reduction of HbA1C [104], and the 
effect of the combination therapy of SU and GP tea was comparable with that of  SU 
combined with metformin [105]. In Paper III, the major anti-diabetic role of GP tea was 
also proven by the reduction of FPG, and by the glucose responses to insulin during 
SIGIT after GP treatment, with the reverse effect after switching to placebo treatment.  
Regarding the possible mechanism by which GP tea decreases plasma glucose levels, 
we have previously isolated an insulin-releasing compound, phanoside, from GP 
extract [64]. However, our present data do not support an increased insulin response to 
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a glucose challenge in GP tea-treated patients, since the 30 minute plasma insulin levels 
in OGTT were not enhanced. The improvement of diabetic control with the combined 
therapy in Paper II occurred without any significant changes in insulin and C-peptide 
levels after adding GP tea to the insulin secretagogue SU. In addition, HOMA-β did not 
indicate that GP tea enhanced beta cell secretion. The anti-diabetic effect of GP tea 
treatment could rather be explained by improved insulin sensitivity, as demonstrated by 
HOMA-IR. With respect to these observations, it appears that GP tea may provide 
improved glycemic control via a mechanism that is independent of the stimulation of 
insulin release, and that does not place any additional burden on defective beta cells. 
This is agreement with another study showing  a significant reduction of HOMA-IR in 
subjects treated by GP extract [106]. In Paper III, the GP tea decreased FPG and the 
glucose response to insulin in the SIGIT steady-state, whereas plasma insulin levels 
during the SIGIT did not change after GP tea treatment in our study population. In a 
previous study, endogenous C-peptide concentrations, reflecting insulin secretion 
during SIGIT, were almost entirely abolished [71]. Thus, these results in Paper III are 
in agreement with our previous findings in Papers I and II [107,108], and indicate that 
the decrease in blood glucose levels is explained by an improvement in insulin 
sensitivity. Interestingly, another experimental study demonstrated that an ethanol 
extract of GP, produced in Vietnam, inhibited protein tyrosine phosphatase 1B activity, 
which may lead to enhanced insulin sensitivity and thereby improved glucose tolerance 
[67].  
In Paper IV, our results in GK rats were consistent with those in humans. Oral 
administration of GP tea for three days did not change the PG levels, whereas long-
term three-week treatment revealed significant decreases in PG. In addition, the three-
week treatment with GP tea significantly improved glucose tolerance and reduced HGO 
compared to the placebo rats. Since the results of an insulin tolerance test reflecting 
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insulin sensitivity mainly in muscle and other extra-hepatic tissues did not differ 
between the two groups, it seems unlikely that the primary effect of GP tea is exerted 
on the extra-hepatic tissues. Thus, these findings suggest that GP-induced 
improvements in glucose tolerance in GK rats is accounted for, at least partly, by 
decreased HGO. Moreover, although addition of adrenaline did increase the HGO in all 
rats, the adrenaline effect tended to be suppressed in GP tea -treated rats.  
HGO plays a prominent role in glucose homeostasis. Insulin decreases HGO by 
activating glycogen synthesis and glycolysis, and by suppressing gluconeogenesis 
[109]. Glycogen is the intracellular stored form of glucose, and its levels in various 
tissues, particularly in liver and skeletal muscle, reflect insulin’s action in stimulating 
glycogen synthase and inhibiting glycogen phosphorylase [110]. We have shown that 
hepatic glycogen content after three weeks of GP tea treatment was significantly lower 
than that after placebo treatment. In parallel, hepatic glycogen synthase activity did not 
differ between GP-treated and placebo rats. In the liver, insulin-dependent glucose 
regulatory functions are controlled by a number of different mechanisms. Among these, 
phosphotyrosine phosphatase 1B (PTP1B) is known to negatively modulate insulin’s 
action on hepatic glucose metabolism through tyrosine dephosphorylation of the insulin 
receptor and/or insulin receptor substrates [111]. GP tea has been demonstrated to 
inhibit PTP1B, and this action has been linked to enhanced insulin sensitivity and 
improved glucose tolerance [67,112]. Interestingly, a more recent study has shown that 
hepatic glycogen content was significantly reduced in PTP1B -/- transgenic mice as 
compared to wild-type controls [113]. Therefore, it can be speculated that GP tea 
improves hepatic insulin sensitivity to some extent through the inhibition of PTP1B. In 
addition, it seems likely that the improvement in hepatic insulin sensitivity is partly 
accounted for by a reduction of gluconeogenesis, as shown by the decreased glucose 
response during the pyruvate tolerance test in the GP tea -treated GK rats. 
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The anti-hyperlipidemic effect was not observed after treatment with GP tea. These 
results differ from those observed in a study of obese Zucker fatty rats, in which 
triglyceride and cholesterol levels were reduced after 4 days of treatment with GP 
extract [66]. The difference between doses and species may be an explanation for these 
divergent outcomes. In addition, GP extract has been reported to exert many other 
effects, such as anti-tumor [114,115], antioxidant and hepatoprotective [106,116], anti-
inflammatory [117], and anti-gastric ulcer effects [118,119]. However, an evaluation of 
these effects of GP was beyond the scope of our study.  
In our studies, there was ideal compliance (100%), and GP tea was well-tolerated. In 
the GP tea groups in Papers I and III, no patient developed abnormalities of the liver or 
renal function tests throughout the study period. In Paper II, no adverse effects were 
documented in the combination treatment of SU and GP tea, compared with SU as 
monotherapy or SU and placebo tea. Compared with the most common combination, 
SU plus metformin, no patients experienced adverse gastrointestinal effects such as 
diarrhea, nausea, epigastric discomfort, and anorexia, which might be the causes of 
treatment discontinuation in some studies [120,121]. In addition, neither hepatoxicity 
nor nephrotoxicity developed, in support of the biosecurity of GP tea used as add-on 
therapy with SU. We used a low dose of the SU, gliclazide, and no patient experienced 
symptoms of hypoglycemia, even when SU was used in combination therapy with GP 
tea. The risk of hypoglycemia often increases in parallel with the dose increment of SU 
[122]; however, with the addition of GP tea, the observed results proved that this tea 
can be efficacious for the maintenance of the effects of low dose SU treatment. During 
our studies, no patients experienced any symptoms of hypoglycemia, and no acute 
hepatoxic or nephrotoxic effects were observed. This notion is supported by a study in 
rats, in which no signs of chronic toxicity were found after a 6-month administration of 
rather high GP tea extract doses (up to 0.75 g/kg per day) [123]. However, larger and 
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longer trials are needed to assess, with higher accuracy, the prevalence of possible 
adverse effects. In addition, further research is needed to determine the durability of GP 
extract's anti-diabetic effect, as well as effects on patient-reported outcomes, morbidity 
and mortality. 
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6 CONCLUSIONS 
 
I. The significant anti-diabetic effects and improved insulin sensitivity of GP 
tea were clearly demonstrated (Paper I), although this randomized, double-
blind, placebo-controlled trial only enrolled a modest number of patients. 
The biosecurity of the extract was indicated clinically, since no 
hepatotoxicity and nephrotoxicity or other acute adverse effects were 
observed in the trial. Therefore, this trial (Paper I) provided a basis for a 
novel, easy access, effective and safe approach to treat type 2 diabetic 
patients using traditional Vietnamese medicine.  
II. As add-on therapy to sulfonylurea, GP extract improved glycemic control, 
and this improvement was sustained over 12 weeks (Paper II). Furthermore, 
there were potential benefits in terms of the maintenance of low-dose SU 
without any symptoms of hypoglycemia. The biosecurity of GP extract was 
suggested clinically, since no hepatotoxicity and nephrotoxicity or other 
acute adverse effects were observed in the trial. Therefore, our results using 
Vietnamese herbal medicine could offer an alternative to the addition of 
other oral medications to treat type 2 diabetic patients. 
III. The GP extract exerted anti-diabetic effects by improving insulin sensitivity 
as the major mechanism, in a placebo-controlled crossover study (Paper III). 
IV. The oral administration of GP extract for three weeks to GK rats exerted 
anti-diabetic effects by reducing plasma glucose levels and suppressing 
HGO levels significantly (Paper IV). The mechanism behind the improved 
hepatic insulin sensitivity may relate to suppression of gluconeogenesis and 
inhibition of PTP1B. 
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